RESEARCH ARTICLE

Role of phospholipase A2 receptor 1 antibody level at diagnosis for long-term renal outcome in membranous nephropathy

Maida Mahmud1, Hans O. Pinnschmidt2, Linda Reinhard1, Sigrid Harendza1, Thorsten Wiech3, Rolf A. K. Stahl1, Elion Hoxha1,*

1 III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 2 Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 3 Division of Nephropathology, Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

* ehoxha@uke.de

Abstract

Background

Membranous nephropathy (MN) is an autoimmune disease induced by circulating antibodies against the podocyte protein phospholipase A2 receptor 1 (PLA2R1-ab) in 80% of patients and represents the leading cause of nephrotic syndrome in adults. PLA2R1-ab levels correlate with disease activity and treatment response. However, their predictive role for long-term renal outcome is not clear.

Methods

The aim of this prospective observational multicenter study was to investigate the predictive role of PLA2R1-ab levels at the time of diagnosis for long-term outcome in a cohort of 243 patients with newly diagnosed biopsy-proven PLA2R1-associated MN. Statistical analyses included Cox proportional hazard models. The primary study endpoint was defined prior to data collection as doubling of serum creatinine or development of end-stage renal disease.

Results

During the median follow-up time of 48 months, 36 (15%) patients reached the study endpoint. Independent predictors for reaching the study endpoint were baseline PLA2R1-ab levels (HR = 1.36, 95%CI 1.11–1.66, p = 0.01), percentage of tubular atrophy and interstitial fibrosis (HR = 1.32, 95%CI 1.03–1.68, p = 0.03), PLA2R1-ab relapse during follow-up (HR = 3.22, 95%CI 1.36–7.60, p = 0.01), and relapse of proteinuria (HR = 2.60, 95%CI 1.17–5.79, p = 0.02). Fifty-four (22%) patients received no immunosuppressive treatment during the study, in 41 (76%) of them PLA2R1-ab spontaneously disappeared during follow-up, 29 (54%) patients had a complete remission of proteinuria, and 19 (35%) had a partial remission. Patients not treated with immunosuppression were more often females and had lower PLA2R1-ab levels, proteinuria, and serum creatinine at baseline compared to patients receiving immunosuppression. However, no conclusion on the efficacy of immunosuppressive treatment can be drawn from this study.
Introduction

Membranous nephropathy (MN) is a common cause of nephrotic syndrome in adults. In 80% of the patients the disease is caused by binding of circulating antibodies to the phospholipase A₂ receptor 1 (PLA₂R1), which is expressed on the surface of podocytes and is the major target antigen [1]. Detection of PLA₂R1 antibodies (PLA₂R1-ab) allows the diagnosis of MN [2–5]. Moreover, PLA₂R1-ab levels are associated with treatment response, remission of proteinuria, relapse of proteinuria, and recurrence of disease after renal transplantation [4, 6–8]. A number of studies have shown that a decrease of PLA₂R1-ab precedes clinical remission (i.e. remission of proteinuria) after immunosuppressive treatment [6,9,10]. Furthermore, patients with detectable PLA₂R1-ab have a higher risk for relapse of proteinuria [11, 12]. Therefore, measurement of PLA₂R1-ab is helpful for the management of patients with MN [13] but the significance of PLA₂R1-ab levels for renal endpoints, such as doubling of serum creatinine or development of end-stage renal disease, is not clear because of the retrospective character of the available studies or the short-term follow-up of the patients [14, 15]. While complete remission of proteinuria is considered a surrogate parameter for long-term renal outcome [16], a better understanding of the clinical relevance of PLA₂R1-ab for long-term prognosis would substantially improve treatment decisions and risk stratification of patients with MN.

In order to better define the role of PLA₂R1-ab levels at the time of diagnosis on long-term renal outcome we conducted a multicenter open prospective observational study in a large cohort of patients with newly diagnosed biopsy-proven PLA₂R1-associated MN.

Material and methods

Patient cohort and study design

Starting from January 2010 all patients with a biopsy-proven diagnosis of MN who fulfilled the study inclusion criteria and provided informed consent to participate in the study were screened for circulating PLA₂R1-ab. Study enrolment and the first measurement of PLA₂R1-ab had to be performed within six months of renal biopsy. Treatment with immunosuppressive agents prior to study start was not allowed. Follow-up visits were performed every three months. PLA₂R1-ab levels, proteinuria, and serum creatinine were measured at every study visit and data were recorded prospectively after each visit. Treatment decisions in enrolled patients were not made per protocol, but by the treating nephrologists, who decided on the therapeutic strategy based on patient characteristics (i.e. proteinuria, nephrotic syndrome, renal function, etc.) and their clinical experience. The primary study endpoint was defined as doubling of serum creatinine in relation to the time of study inclusion or development of end-stage renal disease, whichever occurred earlier. Depletion of PLA₂R1-ab was defined as PLA₂R1-ab falling below 14 U/ml. Remission of proteinuria was defined as proteinuria < 3.5
g/24h and at least 50% reduction from the time of study inclusion. Complete remission of proteinuria was defined as proteinuria < 0.5 g/24h. Relapse of PLA2R1-ab was defined as PLA2R1-ab increasing from < 14 U/ml to a level higher than 20 U/ml. Relapse of proteinuria was defined as proteinuria > 3.5 g/24h and at least doubling of proteinuria compared to the lowest value during the period of remission.

Glomerular disease stages were assessed by electron microscopy according to Ehrenreich and Churg [17]. At study inclusion PLA2R1-ab measurement was performed by ELISA, indirect immunofluorescence (IFT) and Western blot, as described before [18]. During follow-up the PLA2R1-ab was measured by ELISA [19]. The study was approved by the local ethics committee of the chamber of physicians in Hamburg and conducted in accordance with the ethical principles stated by the Declaration of Helsinki. Informed consent was obtained from all participating patients.

**Statistical analyses**

Descriptive analyses of continuous data are presented as median and 1st and 3rd quartile unless stated otherwise. For categorical data, absolute counts and percentages are reported. Mann-Whitney U and Kruskal-Wallis tests were employed for comparisons of continuous variables while Fisher’s exact tests were used for group-wise comparisons of categorical variables. Multivariate relationships among variables were explored by nonlinear categorical principal component analysis [20, 21]. A two-dimensional solution was chosen and the component loadings of the variables are graphically presented.

Uni- and multivariate Cox regression analyses were used to assess the effect of independent variables on the time to event for the study endpoint. Time-dependent covariates were computed and used to test the proportional hazards assumption for individual independent variables. Multivariate Cox regression analyses started with an initial model containing only additive terms of independent variables and their corresponding time-dependent terms if either one, the additive, or the time-dependent term, had displayed a significant effect in the univariate analyses. Non-significant terms were stepwise eliminated from the model using a hierarchical backward approach [22]. Results of Cox regression analyses are presented as hazard ratios with corresponding 95% confidence intervals and p-values. Right-skewed covariates were log2-transformed to reduce the over-proportional impact of extremely high data values on computations of hazard ratios while at the same time trying to ensure linear relationships to outcomes. These relationships were evaluated via visual examinations of scatter plots of martingale residuals of Cox regressions not containing any covariates in the model versus the respective covariate of interest.

Detailed description of the statistical analyses for the primary study endpoint as well as for the secondary endpoints depletion of PLA2R1-ab, relapse of PLA2R1-ab, remission of proteinuria, and relapse of proteinuria are included in the supplemental material. Statistical significance was defined as p < 0.05. All tests were two-tailed. All statistical analyses were done using SPSS version 25.0 (IBM, Armonk, New York).

**Immunohistochemical staining of renal biopsies for PLA2R1**

For PLA2R1 immunohistochemical analyses slides were deparaffinized, pre-treated in citrate buffer (pH 6.2) for 15 min at 120 °C and cooled down in iced water (10 min). After rinsing in 99% ethanol, slides were incubated for 10 min with normal serum (Vector S2000; VectorLaboratories, Burlingame, CA) followed by PLA2R1-antibodies (polyclonal antibody from rabbit, 1:3000, HPA 012657, Sigma-Aldrich, St. Louis, MO) overnight at 4°C. The slides were then washed in PBS, incubated with polymer 1 (Zytomed Zytchem-Plus AP Polymer-KitPOLAP),
rinsed in PBS and incubated with polymer 2 (Zytomed Zytochem-Plus AP Polymer-Kit POLAP). After washing in PBS, slides were stained in new fuchsin naphthol As-Bi phosphate substrate mixture (30 min) followed by 1 min of nuclear staining in hemalaun (Mayer).

Results

Clinical baseline characteristics

A total of 312 consecutive patients with biopsy-proven MN were tested for the presence of PLA₂R1-ab in the serum. At study inclusion PLA₂R1-ab were detectable by ELISA and IFT in 222 patients. In addition, 21 patients were tested positive for PLA₂R1-ab by IFT, but not in the ELISA. These 21 sera were additionally analysed by Western blot and all were positive for PLA₂R1-ab, confirming the results of the IFT. For 152 patients the renal biopsy was stained for PLA₂R1 and confirmed the diagnosis of PLA₂R1-associated MN in all cases. Sixty-nine patients were tested negative for PLA₂R1-ab by ELISA, IFT, and Western blot and were not included in the study. In five of these patients renal biopsy showed an enhanced staining for PLA₂R1. Taken together, 243 consecutive patients with the histologic diagnosis of MN and positive PLA₂R1-ab in the serum were included in this prospective multicenter study. The median follow-up time was 48.0 months (1st to 3rd quartile: 27.0 to 63.0 months), resulting in a cumulative follow-up time of 916.7 patient-years. The clinical baseline characteristics of the study cohort are presented in Table 1. After dividing the study cohort in tertiles according to the PLA₂R1-ab level at baseline, patients with the highest antibody levels were older, had higher proteinuria and more tubulointerstitial fibrosis, although the absolute difference in the percentage of tubulointerstitial fibrosis between the groups was small. At baseline 63 (26%) patients had an impaired renal function defined as eGFR < 60 ml/min/1.73m² (S1 Table). In addition to having more severe renal damage (serum creatinine, GFR, tubular atrophy and...

Table 1. Clinical baseline characteristics of patients with low (tertile 1), medium (tertile 2), or high (tertile 3) PLA₂R1-ab level.

|                        | Tertile 1 | Tertile 2 | Tertile 3 | P-value |
|------------------------|-----------|-----------|-----------|---------|
| Number of Patients     | 78        | 79        | 79        | na      |
| Age—years (median, 1st - 3rd quartile) | 47.0 (36.0–61.3) | 55.0 (43.0–67.0) | 58.0 (46.0–69.0) | 0.02 |
| Male sex (%)           | 50 (64%)  | 60 (76%)  | 58 (73%)  | 0.2     |
| Proteinuria—g/24h (median, 1st - 3rd quartile) | 6.4 (3.6–8.6) | 6.6 (5.0–9.8) | 8.4 (5.0–11.8) | 0.01 |
| Serum creatinine—mg/dl (median, 1st - 3rd quartile) | 0.9 (0.8–1.3) | 1.0 (0.8–1.2) | 1.0 (0.9–1.3) | 0.3     |
| eGFR, CKD-EPI—mL/min/1.73 m² (median, 1st - 3rd quartile) | 87.0 (62.5–103.4) | 87.7 (61.4–103.6) | 75.2 (49.2–93.5) | 0.1     |
| PLA₂R1-ab level, U/ml (median, 1st - 3rd quartile) | 36.0 (10.4–57.9) | 127.4 (95.3–155.4) | 452.0 (274.7–729.4) | <0.001 |
| Time between renal biopsy and study inclusion—months (median, 1st - 3rd quartile) | 0.5 (0.2–1.0) | 0.5 (0.0–1.0) | 0.7 (0.0–1.0) | 0.5     |
| % of tubulointerstitial space with tubular atrophy and interstitial fibrosis (median, 1st - 3rd quartile) | 5 (0–20) | 5 (0–10) | 10 (5–20) | 0.01 |
| Glomerular lesions in renal biopsies (EM) * | Stage I (%) | 4 (5%) | 5 (7%) | 5 (7%) | 0.2 |
|                        | Stage II (%) | 34 (46%) | 48 (66%) | 41 (55%) |
|                        | Stage III (%) | 16 (22%) | 12 (16%) | 14 (19%) |
|                        | Stage IV (%) | 20 (27%) | 8 (11%) | 15 (20%) |

eGFR—estimated GFR according to the CKD-EPI formula; EM—electron microscopy; PLA₂R1-ab—PLA₂R1-antibody.

*—data on Glomerular lesions in renal biopsies (EM) are available for 222 patients

https://doi.org/10.1371/journal.pone.0221293.t001
interstitial fibrosis) these patients were also significantly older and had higher proteinuria compared to patients with preserved renal function (eGFR > 60 ml/min/1.73m²) at baseline. PLA₂R₁-ab levels were not significantly different between the two groups.

The component loadings computed by nonlinear categorical principal component analysis to examine relationships among clinical parameters at baseline reveal positive correlations among serum creatinine levels at baseline, extent of tubular atrophy and interstitial fibrosis, and age of patients while these clinical parameters show a strong negative correlation with eGFR. PLA₂R₁-ab appears unrelated to any of these clinical baseline parameters (S1 Fig).

**Clinical variables associated with the primary study endpoint**

Thirty-six (15%) patients reached the study endpoint defined as doubling of serum creatinine or development of end-stage renal disease. These patients reached the study endpoint after a median follow-up time of 18.0 months (1st to 3rd quartile: 12.0 to 42.0 months), 14 (5.8%) of these patients developed end-stage renal disease. Results of univariate Cox regression analyses testing all independent variables and their time-dependent terms individually are provided in S2 Table. In the multivariate Cox regression analysis higher PLA₂R₁-ab levels at baseline significantly increased the risk for reaching the study endpoint (log₂[PLA₂R₁-ab levels]: HR = 1.36, 95%CI 1.11–1.66, p = 0.01, Fig 1). Of all other baseline clinical parameters, only the percentage of tubular atrophy and interstitial fibrosis was a statistically significant risk factor (log₂[tubular atrophy and interstitial fibrosis] HR = 1.32, 95%CI 1.03–1.68, p = 0.03). After analyzing all variables for time-varying effects during follow-up a significant time-dependent change of the variable effect was found for serum creatinine, showing that the variable effect of serum creatinine for the study endpoint significantly increases during the follow-up time. In this multivariate Cox regression analysis we also included parameters associated with disease progression and treatment response during follow-up and found that relapse of PLA₂R₁-ab during follow-up and a relapse of proteinuria significantly increased the risk for reaching the study endpoint (HR = 3.22, 95%CI 1.36–7.60, p = 0.01 and HR = 2.60 95%CI 1.17–5.79, p = 0.02, respectively).

Patients who reached the study endpoint had significantly higher PLA₂R₁-ab, higher serum creatinine levels, lower eGFR, more extended tubular atrophy and interstitial fibrosis at baseline, while during follow-up they more often failed to deplete PLA₂R₁-ab and had significantly less often a complete remission of proteinuria compared to patients who did not reach the study endpoint (Table 2).

**Secondary study endpoints**

Since relapse of PLA₂R₁-ab and proteinuria during follow-up significantly increased the risk for reaching the primary study endpoint, we analysed in a next step which clinical parameters might influence the outcome of PLA₂R₁-ab and proteinuria during follow-up (supplemental methods). We first performed a univariate Cox regression analysis to identify clinical variables potentially linked to depletion of PLA₂R₁-ab (S3 Table), relapse of PLA₂R₁-ab (S4 Table), remission of proteinuria (S5 Table), and relapse of proteinuria (S6 Table). In a second step we performed multivariate Cox regression analyses and identified PLA₂R₁-ab levels at baseline to be a significant predictor of depletion of PLA₂R₁-ab, remission of proteinuria, and relapse of proteinuria during follow-up (log₂[PLA₂R₁-ab levels]: HR = 0.71, 95%CI 0.63–0.79, p<0.001; HR = 0.92, 95%CI 0.86–0.99, p = 0.02; and HR = 1.15, 95%CI 1.03–1.28, p = 0.01, respectively; S2 and S3 Figs). PLA₂R₁-ab levels at baseline were also predictive for relapse of PLA₂R₁-ab during follow-up in the univariate analysis, however, in the multivariate analysis this association was not statistically significant (log₂[PLA₂R₁-ab levels]: HR 1.12, 95%CI 0.99–1.26,
The only other parameter associated with depletion of PLA₂R1-ab in the multivariate analysis was use of immunosuppressive treatment (HR 4.15, 95%CI 2.84–6.06, p < 0.001; S2 Fig). We also found a significant time-dependent change of the variable effect for PLA₂R1-ab and age, showing that the effect of these variables for the endpoint significantly changes during the follow-up time.

In addition to the PLA₂R1-ab levels at baseline, depletion of PLA₂R1-ab, and proteinuria at baseline were also significant risk factors for remission of proteinuria (HR = 2.56, 95%CI 1.81–
3.61, p<0.001 and log₂(proteinuria): HR = 0.65, 95%CI 0.50–0.83, p<0.001, respectively; S3A Fig). Moreover, proteinuria and serum creatinine showed a significant time-dependent change of the variable effect during the follow-up time. In addition to PLA₂R1-ab levels, serum creatinine at baseline, relapse of PLA₂R1-ab, and partial remission of proteinuria compared to complete remission significantly increased the risk for a relapse of proteinuria (log₂[serum creatinine]: HR = 1.77, 95%CI 1.24–2.52, p = 0.01; HR = 3.06, 95%CI 1.81–5.16, p<0.001; and HR = 10.00, 95%CI 5.97–16.76, p<0.001, respectively; S3B Fig).

Patients treated with immunosuppression or supportive care only

During the study, 189 (78%) patients were treated with immunosuppressive agents in addition to supportive medication, while 54 (22%) patients received supportive medication only (S7 Table). Patients treated with immunosuppression were significantly more often male (p = 0.03), had higher PLA₂R1-ab levels (p<0.001), higher proteinuria (p<0.001), higher serum creatinine at baseline (p = 0.01), and more often a relapse of PLA₂R1-ab during follow-up (p = 0.04) compared to the 54 patients who were treated with supportive care only. However, the differences in PLA₂R1-ab levels and proteinuria between patients treated with immunosuppression and patients receiving only supportive medication diminished during follow-up, most probably as an effect of the started immunosuppressive therapy, and were no longer

Table 2. Clinical characteristics of patients who reached the primary study endpoint compared to patients who did not.

|                                | Complete cohort | No DSC | DSC | P-value |
|--------------------------------|-----------------|--------|-----|---------|
| Number of Patients             | 243             | 207    | 36  | na      |
| Age—years (median, 1st - 3rd quartile) | 55.0 (43.0–65.5) | 54.0 (42.0–64.0) | 59.5 (50.3–69.0) | 0.07 |
| Male sex (%)                   | 171 (70%)       | 145 (70%) | 26 (72%) | 0.8    |
| Proteinuria—g/24h (median, 1st - 3rd quartile) | 7.0 (4.8–10.6) | 6.8 (4.7–10.5) | 7.8 (4.9–10.6) | 0.8    |
| Serum creatinine—mg/dl (median, 1st - 3rd quartile) | 1.0 (0.8–1.3) | 1.0 (0.8–1.2) | 1.2 (0.9–1.9) | <0.001 |
| eGFR, CKD-EPI—mL/min/1.73 m² (median, 1st - 3rd quartile) | 82.7 (58.0–100.5) | 84.7 (62.6–102.1) | 53.7 (31.3–95.4) | 0.01 |
| PLA₂R1-ab level, U/ml (median, 1st - 3rd quartile) | 127.7 (59.3–276.6) | 104.9 (53.0–235.5) | 315.2 (132.3–749.1) | <0.001 |
| Time between renal biopsy and study inclusion–months (median, 1st - 3rd quartile) | 0.5 (0.0–1.0) | 0.5 (0.0–1.0) | 0.5 (0.2–1.0) | 0.9    |
| % of tubulointerstitial space with tubular atrophy and interstitial fibrosis (median, 1st - 3rd quartile) | 5 (0–20) | 5 (0–15) | 20 (10–50) | <0.001 |
| Glomerular lesions in renal biopsies (EM) * | | | | |
| Stage I (%)                    | 14 (6%) | 14 (7%) | 0 (0%) | 0.1 |
| Stage II (%)                   | 123 (55%) | 102 (54%) | 21 (62%) | 0.5 |
| Stage III (%)                  | 42 (19%) | 39 (21%) | 3 (9%) | 0.2 |
| Stage IV (%)                   | 43 (19%) | 33 (18%) | 10 (29%) | 0.1 |
| Immunosuppressive treatment during follow-up (%) | 189 (78%) | 158 (76%) | 31 (86%) | 0.3 |
| PLA₂R1-ab persistent throughout the follow-up (%) | 49 (20%) | 34 (16%) | 15 (42%) | 0.001 |
| Relapse of PLA₂R1-ab during follow-up (%) | 72 (30%) | 60 (29%) | 12 (33%) | 0.7 |
| Remission of proteinuria       | | | | |
| CR (%)                         | 135 (56%) | 123 (59%) | 12 (33%) | 0.01 |
| PR (%)                         | 81 (33%) | 67 (32%) | 14 (39%) | 0.4 |

DSC—doubling of serum creatinine; eGFR—estimated GFR according to the CKD-EPI formula; EM—electron microscopy; PLA₂R1-ab—PLA₂R1-antibody; CR—complete remission; PR—partial remission

*—data on Glomerular lesions in renal biopsies (EM) are available for 222 patients

https://doi.org/10.1371/journal.pone.0221293.t002
significant after six months and nine months, respectively (Fig 2). Patients treated with immunosuppressants had higher serum creatinine levels compared to patients treated with supportive medication only and this difference persisted throughout the study follow-up.

Natural course and outcome of PLA2R1-associated MN

We further analysed the 54 patients who were treated with supportive care only, in order to better understand the natural course of disease, when no immunosuppressive treatment is given. Forty-one (76%) of these patients spontaneously reduced their PLA2R1-ab levels during follow-up (S8 Table). The only statistically significant difference between the two patient cohorts at baseline were the PLA2R1-ab levels. Patients with spontaneous reduction of PLA2R1-ab levels had significantly more often a remission of proteinuria (98% of patients, 71% complete remission and 27% partial remission) compared to patients with persistent PLA2R1-ab (62% of patients, 0% complete remission and 62% partial remission). Patients with spontaneous reduction of PLA2R1-ab reached less often the study endpoint, however, this difference did not reach statistical significance (5% versus 23%, p = 0.08).

Effect of individual immunosuppressive treatments

The initial immunosuppressive agent chosen in most patients was cyclosporine A (81 patients, in 66 of them combined with steroids), followed by oral cyclophosphamide (39 patients, in 38 of them combined with steroids), intravenous (iv) cyclophosphamide (35 patients, in 28 of them combined with steroids), and rituximab (19 patients, in six of them combined with steroids). Immunosuppressive treatment was started at 3.0 months (1st to 3rd quartile: 0.0 to 6.0 months) after inclusion in the study. Proteinuria, renal function, and PLA2R1-ab levels were not significantly different between study inclusion and start of treatment (S9 and S10 Tables).

In some of the patients, data on PLA2R1-ab, proteinuria, and serum creatinine were collected at a short time after start of immunosuppressive treatment, namely one week and four weeks (Fig 3). We noticed a decrease of PLA2R1-ab levels already after one week in all treatment groups, which was most pronounced in patients treated with oral cyclophosphamide (86%), followed by rituximab (47%), iv cyclophosphamide (40%), and cyclosporine A (18%) (Fig 3A). After four weeks and three months the PLA2R1-ab levels had decreased in all groups by 74%– 94% and 85%– 97%, respectively (Fig 3B and 3C). After one week, proteinuria was only reduced in patients treated with cyclosporine A (26%), and rituximab (5%), but not in patients treated with cyclophosphamide (Fig 3D). After four weeks, proteinuria fell by 40% in all groups, except for patients treated with rituximab (Fig 3E). Only after three months a decrease of proteinuria by 25%– 54% was observed in all groups (Fig 3F). Serum creatinine decreased after one week in patients treated with rituximab (7%), but increased by 5%, 14%, and 17% in patients treated with oral cyclophosphamide, cyclosporine A, and iv cyclophosphamide, respectively (Fig 3G). After four weeks, serum creatinine fell by 6%– 12% in all groups, except patients treated with cyclosporine A, in whom serum creatinine increased by 18% (Fig 3H). This pattern was also observed at three months, when a decrease of serum creatinine by 6%– 19% was observed in all groups, except patients treated with cyclosporine A, in whom serum creatinine increased by 18% (Fig 3I). In 43 patients treated with cyclosporine A, we were able to analyse data on serum creatinine at the time when cyclosporine A was stopped and within 3 months after cessation of treatment with cyclosporine A. Within this short time period (median 2.0 months, 1st to 3rd quartile: 1.0 to 3.0 months) serum creatinine decreased by 9.1% in these patients.

In every treatment group in almost half of the patients the initial immunosuppressive treatment was changed from one medication to another (42% of patients treated with rituximab,
46% of patients treated with oral cyclophosphamide, 52% of patients treated with cyclosporine A and 57% of patients treated with iv cyclophosphamide). However, no statistically significant differences were observed between the baseline clinical characteristics and outcome parameters of patients who needed a second line immunosuppressive treatment and patients who did not need a second line immunosuppressive treatment (S11 Table).

Discussion

The identification of PLAS1R as the major target antigen in MN has led to significant improvements in the diagnosis and treatment of MN [1, 13]. The role of PLAS1R-ab as a biomarker for disease activity and treatment response has been shown in several studies, but almost all of these studies had a retrospective design and were built on short-term surrogate endpoints like proteinuria [4, 6, 8, 11, 12, 23]. The identification of biomarkers for hard renal endpoints in patients with MN is important not only for treatment strategies, but also for the design of future therapeutic studies. Some studies analysing the role of PLAS1R-ab for the outcome of renal function only had a retrospective design, short term follow-up, and the renal endpoint was defined as a rather small increase in renal retention parameters [14, 15].

This is the first prospective study to investigate the predictive role of PLAS1R-ab for long-term clinical outcome, i.e. doubling of serum creatinine in a large cohort of patients with newly diagnosed PLAS1R1-associated MN. High PLAS1R-ab levels at baseline were found to be a significant risk factor for doubling of serum creatinine. The hazard ratio of 1.36 per 2-fold-increase of PLAS1R-ab levels underscores their relevance for the clinical outcome of patients with MN. At baseline, only parameters indicating renal damage, e.g. tubular atrophy and interstitial fibrosis, were found to be a risk factor for reaching the study endpoint in addition to the PLAS1R-ab level. The IFT was more sensitive than the ELISA for detection of PLAS1R-ab, as we have shown earlier [2, 6]. At the same time, PLAS1R-ab levels were not closely related to any of the baseline clinical characteristics as shown in the nonlinear categorical principal component analysis which indicated that serum creatinine, tubular atrophy and interstitial fibrosis, and age of patients were sharing close relations to a common dimension. Our data also confirmed the relevance of clinical parameters associated with disease progression and treatment response during follow-up. Relapse of PLAS1R-ab and proteinuria during follow-up were significant factors for loss of renal function. Importantly, high PLAS1R-ab levels at baseline were identified as a risk factor for almost every parameter of disease activity during follow-up (depletion of PLAS1R-ab, remission of proteinuria, and relapse of proteinuria), in addition to the study endpoint. Moreover, depletion of PLAS1R-ab was predictive for remission of proteinuria, while relapse of PLAS1R-ab was predictive for relapse of proteinuria. As has been shown before [16], patients with a partial remission of proteinuria had a much higher risk for relapse of proteinuria compared to patients with a complete remission of proteinuria (HR = 10.0).
Additionally, we had the chance to study the natural course of PLA₂R₁-associated MN, since 22% of the patients were treated with supportive medication only. Since these patients had lower PLA₂R₁-ab levels, proteinuria, and serum creatinine at baseline compared to patients treated with immunosuppression, they might represent a cohort of patients with low disease activity. In most of these patients PLA₂R₁-ab spontaneously disappeared during follow-up. This is an important observation, since it suggests that in a considerable number of patients unknown mechanisms lead to spontaneous disappearance of PLA₂R₁-ab from the circulation. A better pathophysiologic characterisation of the mechanisms responsible for this phenomenon might lead to new treatment options for MN.

In a part of the study cohort we analysed the development of PLA₂R₁-ab, proteinuria, and serum creatinine within a very short time after start of immunosuppression. As we had observed in single cases of MN before [24], we found a very rapid decline of PLA₂R₁-ab upon immunosuppressive treatment, in some patients within a week. After four weeks, PLA₂R₁-ab levels had declined by almost 80%, while proteinuria declined at a slower rate by about 40% at four weeks, which also has been observed by others [9, 10]. An intriguing finding in our cohort was that four weeks and three months after start of immunosuppressive treatment serum creatinine declined in all treatment groups, except in patients treated with cyclosporine A, in whom serum creatinine increased by 18% at both time points. The very short latency of this effect and the fact that within three months after cessation of cyclosporine A serum creatinine decreased by 9.1% suggest that these findings represent a hemodynamic effect of cyclosporine A. Taken together, we found no significant difference in the effect of the different immunosuppressants on PLA₂R₁-ab or proteinuria in our study cohort since in every treatment group immunosuppressive treatment had to be changed because of treatment failure or adverse effects in 42% - 57% of the patients. The identification of biomarkers, which may allow a prognosis on the efficacy of a specific immunosuppressive treatment in individual patients would be a significant improvement for the management of patients with MN.

Our study has a number of limitations. This was not a randomized controlled study, therefore no final conclusion can be made on the efficacy of the individual immunosuppressive treatments, especially concerning their long-term efficacy on renal function. Moreover, patients treated only with supportive medication might represent a subclass of patients with low disease activity, rather than the random MN patient in the daily clinical routine. Nonetheless, considering the good outcome of disease in these patients, their identification is an unmet need in clinical routine.

PLA₂R₁-ab at baseline are an important risk factor for the long-term renal outcome of patients with MN and should therefore be embedded in the decision making and treatment management of these patients. Spontaneous disappearance of PLA₂R₁-ab from the circulation is not uncommon and associated with a very good outcome. A better understanding of the immunologic mechanisms leading to this finding might lead to new treatment options for MN.

Supporting information

S1 Fig. Component loading vectors of all clinical baseline variables. The cosine of the angle between the component loading vectors of the variables represents the correlation among the respective variables in the shown two-dimensional solution. An angle close to 0° indicates
high positive correlation, an angle close to 180˚ indicates negative correlation, angles around 90˚ indicate no correlation. The length of a vector indicates the importance of the respective variable for the two-dimensional solution. eGFR: estimated GFR based on the CKD-EPI formula. PLA$_2$R1-ab: PLA$_2$R1 antibody.

S2 Fig. Multivariate Cox regression analysis for depletion and relapse of PLA$_2$R1-ab. A: PLA$_2$R1-ab levels at baseline and use of immunosuppressive treatment were the only variables significantly associated with depletion of PLA$_2$R1-ab during follow-up. The variable PLA$_2$R1-ab level was transformed to its binary logarithm for this analysis. We adjusted the analysis for time-varying effects during follow-up and found a significant time-dependent change of the variable effect for both PLA$_2$R1-ab levels and age. However, the effect of age for the endpoint was not significant. B: Use of immunosuppression was the only variable identified as a significant risk factor for relapse of PLA$_2$R1-ab. 95%CI: 95% Confidence Interval; HR: hazard ratio; PLA$_2$R1-ab: PLA$_2$R1-antibody.

S3 Fig. Multivariate Cox regression analysis for remission and relapse of proteinuria. A: PLA$_2$R1-ab levels, proteinuria at baseline and depletion of PLA$_2$R1-ab levels during follow-up were risk factors for remission of proteinuria. We adjusted the analysis for time-varying effects during follow-up and found a significant time-dependent change of the variable effect for both proteinuria and serum creatinine. However, the effect of serum creatinine for the study end point was not significant. B: PLA$_2$R1-ab levels, serum creatinine at baseline, relapse of PLA$_2$R1-ab levels and partial remission of proteinuria (compared to complete remission) were identified as significant risk factors for relapse of proteinuria. The variables PLA$_2$R1-ab level, proteinuria, and serum creatinine were transformed to their binary logarithm prior to using them in the Cox regression analyses. 95% CI: 95% confidence interval; HR: hazard ratio; PLA$_2$R1-ab: PLA$_2$R1-antibody.

S1 Table. Clinical baseline characteristics and outcomes of patients with eGFR below or higher than 60 mL/min/1.73 m$^2$ at baseline. eGFR–estimated GFR according to the CKD-EPI formula; PLA$_2$R1-ab–PLA$_2$R1-antibody.

S2 Table. Univariate Cox regression analysis to identify clinical parameters predictive for the study endpoint. In the analyses of independent variables measured at baseline we adjusted the analysis for potential time-varying effects during follow-up, while for independent variables representing events measured during follow-up we adjusted the effect of the variable for the time when its event occurred. This table presents results of each variable both with and without adjusting for these time-dependent effects. Un-adjusted analyses consider only a main effect term for each variable. Analyses of baseline variables which were adjusted for time-varying effects consider a main effect term (reflecting the initial effect of the variable) and a time-dependent term (reflecting the change of the variable effect during time). Analyses adjusted for time-varying effects of event variables measured during follow-up consider only a time-dependent term (reflecting the effect of the variable from the time when its event occurs). 95% Conf. Interval: 95% Confidence Interval; PLA$_2$R1-ab: PLA$_2$R1-antibody; Time-dep.: time-dependent; CR: complete remission; PR: partial remission.

S3 Table. Univariate Cox regression analysis for depletion of PLA$_2$R1-ab. In the analyses of independent variables measured at baseline we adjusted the analysis for potential time-varying
effects during follow-up. In this table we present results of each variable both with, and without adjusting for these time-dependent effects. Unadjusted analyses consider only a main effect term for each variable. Analyses of baseline variables which were adjusted for time-varying effects consider a main effect term (reflecting the initial effect of the variable) and a time-dependent term (reflecting the change of the variable effect during time). In the analysis of “use of immunosuppressive treatment” when adjusting for time-varying effects we consider only a time-dependent term (reflecting the effect of the variable from the time when the event occurs–immunosuppression is started). 95% Conf. Interval: 95% Confidence Interval; PLA\textsubscript{2}R1-ab: PLA\textsubscript{2}R1-antibody; Time-dep.: time-dependent.

S4 Table. Univariate Cox regression analysis for relapse of PLA\textsubscript{2}R1-ab. In the analyses of independent variables measured at baseline we adjusted the analysis for potential time-varying effects during follow-up. In this table we present results of each variable both with, and without adjusting for these time-dependent effects. Unadjusted analyses consider only a main effect term for each variable. Analyses of baseline variables which were adjusted for time-varying effects consider a main effect term (reflecting the initial effect of the variable) and a time-dependent term (reflecting the change of the variable effect during time). In the analysis of “use of immunosuppressive treatment” when adjusting for time-varying effects we consider only a time-dependent term (reflecting the effect of the variable from the time when the event occurs–immunosuppression is started). 95% Conf. Interval: 95% Confidence Interval; PLA\textsubscript{2}R1-ab: PLA\textsubscript{2}R1-antibody; Time-dep.: time-dependent.

S5 Table. Univariate Cox regression analysis for remission of proteinuria. In the analyses of independent variables measured at baseline we adjusted the analysis for potential time-varying effects during follow-up. In this table we present results of each variable both with, and without adjusting for these time-dependent effects. Unadjusted analyses consider only a main effect term for each variable. Analyses of baseline variables which were adjusted for time-varying effects consider a main effect term (reflecting the initial effect of the variable) and a time-dependent term (reflecting the change of the variable effect during time). Analyses adjusted for time-varying effects of event variables measured during follow-up consider only a time-dependent term (reflecting the effect of the variable from the time when its event occurs). 95% Conf. Interval: 95% Confidence Interval; PLA\textsubscript{2}R1-ab: PLA\textsubscript{2}R1-antibody; Time-dep.: time-dependent.

S6 Table. Univariate Cox regression analysis for relapse of proteinuria. We adjusted in the analyses of independent variables measured at baseline for potential time-varying effects during follow-up. In this table we present results of each variable both with, and without adjusting for these time-dependent effects. Unadjusted analyses consider only a main effect term for each variable. Analyses of baseline variables which were adjusted for time-varying effects consider a main effect term (reflecting the initial effect of the variable) and a time-dependent term (reflecting the change of the variable effect during time). Analyses adjusted for time-varying effects of event variables measured during follow-up consider only a time-dependent term (reflecting the effect of the variable from the time when its event occurs). 95% Conf. Interval: 95% Confidence Interval; PLA\textsubscript{2}R1-ab: PLA\textsubscript{2}R1-antibody; Time-dep.: time-dependent; CR: complete remission; PR: partial remission.

S7 Table. Baseline clinical characteristics of patients who received immunosuppression or supportive treatment only. DSC–doubling of serum creatinine; eGFR–estimated GFR.
according to the CKD-EPI formula; PLA₂R₁-ab–PLA₂R₁-antibody; CR–complete remission; PR–partial remission

S8 Table. Baseline clinical characteristics of patients who only received supportive treatment. Patients are grouped depending on whether PLA₂R₁-ab persisted in the circulation during follow-up. DSC–doubling of serum creatinine; eGFR–estimated GFR according to the CKD-EPI formula; PLA₂R₁-ab–PLA₂R₁-antibody; CR–complete remission; PR–partial remission

S9 Table. Clinical characteristics at baseline and the time of treatment start for patients who received immunosuppressive therapy. Patients are grouped depending on the first immunosuppressive treatment they received. In some cases immunosuppressive treatment was started at the time between two study visits, therefore data on proteinuria, serum creatinine and PLA₂R₁-ab levels were not available at the exact time when immunosuppression was started. These patients were not included in these analyses. Other immunosuppressants were only rarely used and therefore not included in these analyses. CYC: cyclophosphamide; CsA: cyclosporine A; RTX: rituximab; iv: intravenous; PLA₂R₁-ab: PLA₂R₁ antibody.

S10 Table. P-values for all differences of clinical characteristics at baseline and the time of treatment start shown in s9 Table. A: p-values for the comparisons between patients in the different treatment groups are presented. B: p-values for the comparisons between the clinical characteristics at baseline compared to the time of start of immunosuppression within the same treatment group are presented. CYC: cyclophosphamide; CsA: cyclosporine A; RTX: rituximab; iv: intravenous; PLA₂R₁-ab: PLA₂R₁ antibody.

S11 Table. Clinical baseline characteristics and outcomes of patients who needed a second line immunosuppressive treatment and those who did not. eGFR–estimated GFR according to the CKD-EPI formula; PLA₂R₁-ab–PLA₂R₁-antibody; CR–complete remission; PR–partial remission.

S1 File. Supplemental methods.

Acknowledgments
We thank Katharina Schulz, Sandra Freyberg and Eugen Kinzler for excellent technical assistance. We thank all patients, colleagues, and collaborators who participated in this study. A list of all colleagues involved in patient recruitment and follow-up is included in the supplemental section of this manuscript.

Author Contributions

Conceptualization: Rolf A. K. Stahl, Elion Hoxha.

Data curation: Maida Mahmud, Sigrid Harendza, Thorsten Wiech.

Formal analysis: Maida Mahmud, Hans O. Pinnschmidt, Linda Reinhard, Sigrid Harendza, Thorsten Wiech, Elion Hoxha.
Funding acquisition: Rolf A. K. Stahl.

Supervision: Rolf A. K. Stahl, Elion Hoxha.

Writing – original draft: Elion Hoxha.

Writing – review & editing: Rolf A. K. Stahl, Elion Hoxha.

References

1. Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009; 361(1):11–21. https://doi.org/10.1056/NEJMoa0810457 PMID: 19571279

2. Hoxha E, Kneißler U, Stege G, Zahner G, Thiele I, Panzer U, et al. Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int. 2012; 82(7):797–804. https://doi.org/10.1038/ki.2012.209 PMID: 22673885

3. Svobodova B, Honsova E, Ronco P, Tesar V, Debiec H. Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy. Nephrol Dial Transplant. 2013; 28(7):1839–1844. https://doi.org/10.1093/ndt/gfs439 PMID: 23223223

4. Hofstra JM, Debiec H, Short CD, Pellé T, Kleta R, Mathieson PW, et al. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol. 2012; 23(10):1735–1743. https://doi.org/10.1681/ASN.2012030242 PMID: 22956816

5. Timmermans SA, Ayalon R, van Paassen P, Beck LH Jr, van Rie H, Wirtz JJ, et al. Anti-phospholipase A2 receptor antibodies and malignancy in membranous nephropathy. J Am Kidney Dis. 2013; 62(6):1223–1225. https://doi.org/10.1053/j.ajkd.2013.07.019 PMID: 24021909

6. Hoxha E, Thiele I, Zahner G, Panzer U, Harendza S, Stahl RA. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J Am Soc Nephrol. 2014; 25(6):1357–1366. https://doi.org/10.1681/ASN.2013040430 PMID: 24610926

7. Stahl R, Hoxha E, Fechner K. PLA2R autoantibodies and recurrent membranous nephropathy after transplantation. N Engl J Med. 2010; 363(5):496–498. https://doi.org/10.1056/NEJMc1003066 PMID: 20818871

8. Ruggenenti P, Debiec H, Ruggiero B, Chianca A, Pellé T, Gaspari F, et al. Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J Am Soc Nephrol. 2015; 26(10):2545–2558. https://doi.org/10.1681/ASN.2014070640 PMID: 25804280

9. Beck LH Jr, Fervenza FC, Beck DM, Bonegio RG, Malik FA, Erickson SB, et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol. 2011; 22(8):1543–1550. https://doi.org/10.1681/ASN.2010111125 PMID: 21784898

10. Dahan K, Debiec H, Plaisier E, Cachanado M, Rousseau A, Waksalman L, et al. Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up. J Am Soc Nephrol. 2017; 28(1):348–358. https://doi.org/10.1681/ASN.2016040449 PMID: 27352623

11. Hoxha E, Harendza S, Pinnschmidt H, Panzer U, Stahl RA. PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system. PLoS One. 2014; 9(10):e110681. https://doi.org/10.1371/journal.pone.0110681 PMID: 25313791

12. Bech AP, Hofstra JM, Brenchley PE, Wetzels JF. Association of anti-PLA2R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2014; 9(8):1386–1392. https://doi.org/10.2215/CJN.10471013 PMID: 25035272

13. De Vriese AS, Glasscock RJ, Nath KA, Sethi S, Fervenza FC. A Proposal for a Serology-Based Approach to Membranous Nephropathy. J Am Soc Nephrol. 2017; 28(2):421–430. https://doi.org/10.1681/ASN.2016070776 PMID: 27777266

14. Kanigicherla D, Gummadova J, McKenzi EA, Roberts SA, Harris S, Nikam M, et al. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int. 2013; 83(5):940–948. https://doi.org/10.1038/ki.2012.486 PMID: 23364522

15. Hoxha E, Harendza S, Pinnschmidt H, Panzer U, Stahl RA. M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy. Clin J Am Soc Nephrol. 2014; 9(11):1883–1890. https://doi.org/10.2215/CJN.03850414 PMID: 25267554
16. Thompson A, Cattran DC, Blank M, Nachmann PH. Complete and Partial Remission as Surrogate End Points in Membranous Nephropathy. *J Am Soc Nephrol*. 2015; 26(12):2930–2937. https://doi.org/10.1681/ASN.2015010091 PMID: 26078365

17. Ehrenreich T, Churg J. Pathology of membranous nephropathy. Path Ann. 1968; 3:145–186.

18. Hoxha E, Beck LH, Jr, Wiece T, Tomas NM, Probst C, Mindorf S, et al. An Indirect Immunofluorescence Method Facilitates Detection of Thrombospondin Type 1 Domain-Containing 7A-Specific Antibodies in Membranous Nephropathy. *J Am Soc Nephrol*. 2017; 28(2):520–531. https://doi.org/10.1681/ASN.2016010050 PMID: 27436855

19. Dähnrich C, Komorowski L, Probst C, Seitz-Polski B, Esnault V, Wetzel S, et al. Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy. *Clin Chim Acta*. 2013; 421:213–218. https://doi.org/10.1016/j.cca.2013.03.015 PMID: 23541686

20. Linting M, Meulman JJ, Groenen PJF, van der Kooij AJ. Nonlinear principal components analysis: introduction and application. Psychol Methods. 2007; 12(3):336–358. https://doi.org/10.1037/1082-989X.12.3.336 PMID: 17784798

21. Linting M, van der Kooij AJ. Nonlinear principal components analysis with CATPCA: a tutorial. *J Pers Assess*. 2012; 94(1):12–25. https://doi.org/10.1080/00223891.2011.627965 PMID: 22176263

22. Kleinbaum DG, Klein M. Logistic regression. A Self-learning Text. 2nd ed. New York: Springer; 2002. pp. 513.

23. Wei SY, Wang YX, Li JS, Zhao SL, Diao TT, Wang Y, et al. Serum anti-PLA2R antibody predicts treatment outcome in idiopathic membranous nephropathy. *Am J Nephrol*. 2016; 43(2):129–140. https://doi.org/10.1159/000445361 PMID: 27058841

24. Hoxha E, Harendza S, Zähner G, Panzer U, Steinmetz O, Fechner K, et al. An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. *Nephrol Dial Transplant*. 2011; 26(8):2526–2532. https://doi.org/10.1093/ndt/gfr247 PMID: 21633097